Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 6/20 | 0.34 |
| ▸ | RARB | P10826 | 6/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | RARG | P13631 | 6/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17485957 | 0.86 | RARB (0.36) | RARARARBRXRARARGABCB1 | |
| SCHEMBL17486024 | 0.85 | BACE1 (0.35) | RARARARBRXRARARGABCB1 | |
| SCHEMBL18573101 | 0.83 | RARB (0.36) | RARARARBRXRARARGLDHA | |
| SCHEMBL17486065 | 0.81 | LDHA (0.32) | LDHA | |
| SCHEMBL17486292 | 0.79 | KMO (0.36) | RARARARBRXRARARGPGR | |
| SCHEMBL18015415 | 0.79 | NPC1 (0.37) | RARARARBRXRARARGABCB1 | |
| SCHEMBL17486007 | 0.78 | JAK2 (0.31) | JAK2JAK1TYK2JAK3LDHA | |
| SCHEMBL17485994 | 0.78 | LDHA (0.31) | LDHA | |
| SCHEMBL16998454 | 0.77 | RARB (0.45) | RARARARBRXRARARGABCB1 | |
| SCHEMBL16998885 | 0.77 | RARB (0.45) | RARARARBRXRARARGABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016124304-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | RARA 2536/4885RARB 2999/4885RXRA 2518/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | RARA 3091/4885RARB 3726/4885RXRA 3458/4885 |
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | RARA 3284/4885RARB 3717/4885RXRA 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.